Older Adults\u27 Understanding of Cardiovascular Risk And Preventive Medication Benefit by Wahl, Elizabeth R.
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
2008
Older Adults' Understanding of Cardiovascular
Risk And Preventive Medication Benefit
Elizabeth R. Wahl
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Part of the Medicine and Health Sciences Commons
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Wahl, Elizabeth R., "Older Adults' Understanding of Cardiovascular Risk And Preventive Medication Benefit" (2008). Yale Medicine
Thesis Digital Library. 467.
http://elischolar.library.yale.edu/ymtdl/467
    
 
 
 
 
 
 
 
Older Adults’ Understanding of Cardiovascular Risk  
And Preventive Medication Benefit 
 
 
 
A Thesis Submitted to the 
Yale University School of Medicine 
in Partial Fulfillment of the Requirements for the 
Degree of Doctor of Medicine 
 
 
 
by 
Elizabeth R. Wahl 
2008 
 OLDER ADULTS’ UNDERSTANDING OF CARDIOVASCULAR RISK AND 
PREVENTIVE MEDICATION BENEFIT 
Elizabeth R. Wahl, Terri R. Fried, and Joseph V. Agostini.  Section of Geriatrics, 
Department of Internal Medicine, Yale University, School of Medicine, New Haven, CT. 
 Medication decision making in older adults with multiple chronic conditions is 
complicated; communication between patients and physicians to establish concordant 
treatment goals can enhance this process.  While patients’ ability to make informed 
decisions about treatment priorities depends on their ability to understand the risks and 
benefits of medications and the likelihood of disease outcomes, patients’ knowledge of 
medication-related benefits is unexplored.  We examined older adults’ estimation of their 
10-year risk of myocardial infarction (MI) and stroke, and the degree to which they 
thought common medications were able to prevent these outcomes. 150 male veterans 
age 65 or older and taking five or more medications (including an aspirin, a statin, or an 
antihypertensive drug) were interviewed at VA Connecticut. Using a bar graph with bars 
representing 0, 10, 25, 50, 75, and 100%, participants were asked to estimate their 10-
year risk of stroke and MI when: a) taking no medications, and b) when taking preventive 
medications (aspirin to prevent MI and stroke; statins to prevent MI; and anti-
hypertensives to prevent stroke).  
 Participants had a mean age of 76 ± 6 years and were on 10 ± 3 medications: 
90% had hypertension, 76% had diabetes, 15% had prior MI, and 12% had prior stroke. 
Framingham data suggest the 10-year risk of MI in this population is close to 25%, which 
decreases to about 15% on aspirin or statins. 130/147 (87%) participants overestimated 
their risk of MI (48% estimated it at 75 or 100% over 10 years), 37 (24%) participants felt 
that aspirin provided at least a 50% absolute risk reduction in MI, and 33% of 
participants felt that statins could reduce MI risk by the same degree. However, 18% of 
participants felt that daily aspirin did not change their MI risk at all, and 20% felt a daily 
 statin did not change their MI risk. For stroke, Framingham data suggest that 10-year 
risk in this population is close to 25%, which decreases to 15% on aspirin and anti-
hypertensives. 128/149 (86%) participants overestimated their stroke risk, with 90 (60%) 
estimating that risk to be 75 or 100%. 46/147 (31%) participants estimated that aspirin 
could reduce provide a 50% absolute risk reduction in 10 year stroke risk, and 39% 
estimated that anti-hypertensives could provide at least a 50% absolute risk reduction. 
18 (12%) participants felt that taking a daily aspirin, and 18% felt that taking a daily anti-
hypertensive did not change their ten-year stroke risk.  
 A large proportion of older males overestimated both their 10 year risk of MI and 
stroke.  They also over- and under-estimated the magnitude of benefit conferred by 
aspirin, statins, and anti-hypertensive drugs in preventing these adverse clinical 
outcomes.  Both findings have important implications for medication decision making, 
since under-estimation of benefits may play a role in non-adherence, while over-
estimation of benefits may result in tolerance of medication side effects with the 
expectation that they provide a greater degree of benefit. This study suggests the need 
for increased patient-physician communication regarding the risks and benefits of 
commonly prescribed preventive medications.  
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Introduction 
 
 Medication prescribing and decision making, particularly in an older population 
with multiple morbidities taking multiple medications, presents challenges for patients 
and physicians alike.  Patients taking multiple medications should have some 
understanding of the risks and benefits conferred by their medications in order to make 
informed decisions about treatment priorities, particularly for those drugs requiring 
lifelong preventive therapy.  
 
Medication Use in Older Adults: the Current Prescribing Milieu 
Current Medication Prescribing Practices in the Elderly    
 With the population in the United States older than 65 growing rapidly, the 
number of people affected by and treated for multiple chronic conditions will continue to 
grow.  Reports from nearly a decade ago using 1999 Medicare claims data found that 32 
percent of Medicare beneficiaries have four or more chronic conditions; moreover, these 
patients are responsible for 79 percent of Medicare program spending (1).  Studies of 
medication use in the ambulatory adult population show that 50 percent of adults who 
are 65 years and older take five or more medications weekly, and 12 percent take ten or 
more medications weekly (2, 3).  
 Current evidence supports multiple medication prescribing for the prevention of 
negative sequelae for many of the most common chronic diseases—hypertension, 
diabetes and ischemic heart disease.  Disease-specific guidelines for these conditions 
recommend that patients take two, three, or more medications per condition for optimal 
management.  For example, the 7th report of the Joint National Committee guidelines for 
management of hypertension were released in 2003, promoting the use of 2 or more 
antihypertensive medications in most patients to achieve goal blood pressure (4). 
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Similarly, revisions in 2003 to the American Diabetes Association guidelines recommend 
that patients take multiple classes of medications to maintain adequate glycemic control, 
in addition to aspirin, statins, and ACE-inhibitors for prevention of cardiovascular and 
renal complications (5).  Recent American Heart Association recommendations for 
management of ischemic heart disease and heart failure support multiple medication 
prescribing to optimize treatment for these conditions as well.  Thus, with the 
development of novel therapies to treat disease, and growing evidence that preventive 
medications can limit disease burden, both the number and complexity of drugs 
prescribed to the elderly has increased.    
 Other factors which contribute to multiple medication prescribing may include the 
number of available prescribed and over-the-counter pharmacotherapies, as well as 
physicians’ ability to treat conditions or symptoms that may have been less treated in the 
past (e.g., reflux disease).  Additionally, direct-to-consumer advertising for management 
of conditions that predominantly affect the elderly, such as hyperlipidemia, osteoarthritis, 
osteoporosis, and dementia, may impact medication prescribing practices (6, 7).   
 
Evidence for Medication Benefit in the Elderly 
 There is a lack of high-quality evidence to guide prescribing practices in older 
patients (6, 8), largely because older persons have been historically excluded from 
participating in clinical trials because of their multiple morbidity and possible cognitive 
impairment (9-11).  Gurwitz et al. report that between 1960 and 1991, 60% of trials 
excluded persons over 75 years old (9).  Less is therefore known about optimal 
prescribing in these patients, as well as the extent to which these medications provide 
benefit relative to harm in this population. Additionally, no study has explored (or could 
easily explore) whether the multiple medications recommended for separate medical 
conditions cumulatively have the same effect as they do individually (8). While there may 
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be clear evidence documented by randomized controlled trials that a certain medication 
prevents a health outcome by a certain amount, few trials exist to test whether multiple 
medication regimens taken by older persons collectively provide the same level of 
preventive or therapeutic benefit as that demonstrated for each medication alone.   
 
Medication Use and Risk for Adverse Medication Outcomes 
 Medications used to treat chronic disease provide benefit to patients by 
preventing hospitalization and disease progression, improving or relieving symptoms, 
and even extending life. However, multiple medication use places older patients at 
increased risk of several important outcomes, including adverse drug events (12), drug 
interactions, increased medication costs (13, 14), and decreased medication adherence 
(15).  A 2004 study of cost-related medication non-adherence among Medicare 
beneficiaries conducted prior to implementation of the Medicare drug benefit showed 
that patients with multiple morbidities were nearly three times as likely to have problems 
with adherence related to medication cost (13).  Chronic disease management (and thus 
multiple medication prescribing) in the elderly is complicated by a need to provide 
adequate management of disease while minimizing drug-related problems.  
 Adverse drug events in the elderly are common and often preventable (12, 16). 
Multiple studies have explored adverse drug events in the elderly in both the inpatient 
and the ambulatory setting. Specific classes of medications, such as psychoactive 
medications, opioids, anti-histamines, and anti-cholinergics have been implicated in 
adverse drug events (17-19).  Previous investigations have shown that simply being on 
four or more medications places patients at increased risk of adverse drug events (17, 
18).  In a study of community-dwelling older adults, participants taking five or more 
medications were three times as likely to have unintended weight loss, and nearly twice 
as likely to have impaired balance after controlling for comorbidity (19).  Gandhi et al. 
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reported that 25 percent of patients age 65 and older in the ambulatory setting had a 
medication-related adverse effect over the course of one month, many of which were a 
result of physicians’ failure to respond to symptoms or patients’ failure to communicate 
these symptoms (6, 20).  Other studies exploring ambulatory patient medication 
knowledge also suggest that patients do not always disclose adverse effects (21, 22).   
 In addition to adverse medication effects, older patients are subject to 
inappropriate medication prescribing, particularly when they are followed by multiple 
health care providers (23). In 2006, a study of ambulatory older veterans taking five or 
more medications found that 65% of participants took a medication that was 
contraindicated, and 57% were taking a medication that was ineffective, not indicated, or 
duplicative (24).  Medication review strategies have been proposed as one means to 
address the risk for these drug-related prescribing problems.     
 
Patient Medication Preferences and a Role for Shared Decision Making  
 Medication decision making for older adults may be especially difficult because of 
the increased likelihood of adverse events and less certain likelihood of benefit (25).  
Improved communication strategies between physicians and patients may help elicit 
patient preferences, beliefs, and health priorities.  Shared decision making and patient-
centered decision making models exist to address these challenges (25-27).  In these 
models, the physician provides the patient with information about a choice, and the 
patient considers individual preferences and health priorities in order to reach a decision 
that is reasonable for the individual patient, and that reflects an understanding of the 
possible ramifications of the decision (26).  In regard to making decisions about 
pharmacotherapies, one core component of the shared decision making model is that 
patients have some understanding of drug risks and benefits, and the risks that may be 
involved with not taking the medication.   
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 Studies of treatment preferences for preventive medications among older adults 
suggest that not all patients are interested in a participatory decision making model (25).  
However, older patients are capable of expressing preferences about treatment trade-
offs and can express a range of thresholds for which they would be willing to accept a 
medication, for example for a preventive treatment (28). One study of 675 older adults in 
the ambulatory setting found that 15% of seniors did not think highly effective, 
inexpensive medications to prevent heart attacks were “worthwhile”, while 22% of 
seniors felt low-yield, costly medications to prevent heart attacks were worthwhile (28).  
This study underscores the capability of seniors to express preferences regarding 
medication benefits and trade-offs. 
 
Medication Knowledge in Older Adults 
Older patients’ understanding of medication roles (health knowledge and health literacy)  
 Taking multiple medications is particularly problematic in the context of an older 
population that may experience age-related changes in cognition. Patients taking five or 
more prescription medications surveyed in ambulatory settings were three times more 
likely to misunderstand medication dosage instructions compared to those taking fewer 
medications (29). Furthermore, poor medication knowledge has been shown to impact 
adherence (30-32). Studies examining medication knowledge usually focus on the extent 
to which adults can state medication indications, dosing schedules, and side effects. In a 
study of 122 British patients over the age of 65, patients were unaware of 25% of both 
their illnesses and their medications (33).  
 In the United States, the Iowa 65+ Rural Health Study surveyed medication 
knowledge in a rural elderly population and found that patients did not know the 
indication for 10% of their drugs (34).  Another study of ambulatory patients of all ages in 
a more urban setting found that 13.5% of patients did not know the indication of at least 
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one of their medications, most commonly cardiovascular drugs, with lack of knowledge 
most likely for patients who were older, black, or had a high school education or less 
(35). Similarly, a survey of 344 ambulatory patients in New Zealand found that 15% of 
patients did not know or misidentified a drug name, 21% did not know its therapeutic 
action, 13% did not know why the doctor prescribed the medication, and 17% of patients 
did not know dosage (36). A related study conducted by Tarn et al. examined physician 
communication during new medication prescribing and found that physicians do not 
consistently educate their patients when they are prescribing new medications: 
physicians communicated a drug name for 74% of new prescriptions, explained the 
purpose for 87% of new drugs, addressed adverse effects for only 35% of new drugs, 
and discussed frequency and timing of dosage 55% of the time (37). These data suggest 
that health knowledge among older patients, particularly seniors who take multiple 
medications, is suboptimal.  
 
Impaired Medication Literacy and Health Outcomes 
 In addition to studies looking at health knowledge among older adults, other 
studies have explored health and medication literacy, defined as the capability to obtain, 
interpret, and understand health information and the ability to use the information and 
services in ways which improve health. The National Health Education Standards, 
published in 1995, also define health literacy as the ability to read prescription drug 
labels, interpret dosages, and use medications appropriately (38).  Although patients 
reading at or below the sixth grade level can correctly state medication dosing 
instructions, this correlates poorly with the ability to demonstrate the number of pills one 
should take daily (29). In patients with chronic diseases such as hypertension and 
diabetes, inadequate functional health literacy limits the effectiveness of traditional 
patient education strategies (39). Poor health literacy in the elderly results in poor self-
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reported health, worse physical and mental health, and has been found to independently 
predict overall and cause-specific morality (40, 41).  
 
Patients’ Beliefs about Medications 
 Patients’ health beliefs also impact their health behaviors, particularly in terms of 
medication use and adherence (42-44). Patients reporting high levels of concern about 
taking medications have lower self-reported adherence (43). Additionally, patients do not 
always openly discuss medication beliefs and behaviors with their physicians, and many 
feel ambivalent about taking medication (42, 45-47). While physicians believe they 
understand patient preferences and priorities in taking medication, they may focus on 
disease-specific outcomes rather than quality-of-life issues (48). There is, however, 
significant variability in the extent to which patients want to be involved in making 
decisions about their medications (25). Thus, some researchers have emphasized the 
importance of concordance between patient and physician health goals rather than 
focusing specifically on medication adherence (49).  
 
Risk Communication Strategies 
Using Numbers to Understand Risk, or Health Numeracy 
 Making choices about medications and health priorities depends both on the way 
in which physicians communicate risk to patients and on patients’ ability to use numbers 
to understand risk, or their health numeracy (50). Health numeracy is the degree to 
which individuals have the capacity to access, process, interpret, communicate, and act 
on numerical, quantitative, graphical, biostatistical, and probabilistic health information 
needed to make effective health decisions (51). Studies asking patients to make trade-
offs between different disease states depend on quantitative methodologies that require 
participants to have a facility with numbers (52).  Low-probability events are especially 
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difficult for patients to understand and for physicians to communicate (53).  Yamagishi 
showed that patients have great difficulty interpreting numerical risk in a study in which 
patients estimated, for example, that death rates of 1286 per 10,000 were rated as more 
risky than death rates of 24.14 per 100 (54).  Additionally, patients have difficulty 
extrapolating long-term risk from annual risk data.  In a study by Fuller et al., older 
patients were told about two treatment options for stroke that each carried a specific 
annual risk. Participants were then asked to estimate their cumulative 10 year risk of 
stroke on each treatment.  Answers varied widely, with the majority dramatically 
overestimating risk (55).  Notably, previous studies assessing physicians’ ability to 
estimate patients’ cardiovascular disease risk suggest they too over- and under-estimate 
risk: Canadian physicians overestimate their patients’ absolute risk of coronary disease 
(56), while British physicians tended to underestimate cardiovascular risk in elderly 
hypertensive patients (57).  
 
 Challenges of Risk Communication   
 Both language and methods used to communicate risk can vary, thus influencing 
the way in which patients make decisions. Concepts such as ‘rare’ or ‘likely’ have 
different implications for medical decisions in different settings and may be understood 
differently by different patients (53, 58). Communicating disease risk and prevention 
benefit clearly is particularly difficult when multiple models—relative risk reduction, 
absolute risk reduction, number needed to treat—are used (58-60). Relative risk 
reduction models are most sensitive to framing effects by physicians and can profoundly 
alter patients’ perceptions of medication benefit (61). A survey of ambulatory patients by 
Misselbrook and Armstrong highlights the difficulties in interpreting patient preferences: 
of 300 ambulatory patients asked to rank whether or not they would want treatment for 
hypertension based on relative risk reduction, absolute risk reduction, number needed to 
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treat, and personal probability of benefit, the percentage of patients wanting treatment 
ranged from 44 to 92%, depending on the model used (62).   
   
Visual tools used in risk communication 
 Images provide an alternate means of communicating risk information and aiding 
patient decision-making. Several studies have examined the utility of graphical displays 
in communicating risk magnitude, relative risk, cumulative risk, uncertainty, and 
interactions among risk factors, although data have yielded conflicting results and 
suggest that individuals’ performance is task-dependent (53, 58, 63, 64). Graphical 
displays evaluated include bar charts, risk ladders, facial displays, line graphs, pie 
charts, and histograms. In a pilot study, Fortin et al. conducted focus group interviews 
with middle age women and presented women with risk information in multiple graphical 
formats, metrics (absolute vs. relative risk reduction, and number needed to treat), and 
time scales; women preferred bar graphs over line graphs, representative faces, and 
survival curves (65). A larger-scale study of web-based patient information for diabetic 
patients found that patients preferred bar chart formats and found other graphs (line 
graphs and facial displays) as well as anchoring information unhelpful (66).  
 Patient preferences do not always correlate with accurate quantitative judgments; 
graphical features that improve accuracy of quantitative reasoning differ from those 
features most likely to alter behavior or intentions (63). Studies looking at accuracy of 
quantitative risk judgments in older adults suggest that risk information is best presented 
and processed using vertical bars with a scale (64). In a study of 216 community-
dwelling adults over 50, people were asked to compare two graphically depicted 
percentages and choose the larger chance of survival or the smaller chance of side 
effects.  Vertical bars with scales were the fastest and most accurately processed, and 
errors occurred most frequently with pie charts and facial displays blocked in at random.       
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Gaps in Current Knowledge 
 
 Older patients’ understanding of medication benefit is largely unexplored in the 
literature.  Although there are studies that describe impaired medication knowledge in 
older patients, as well as studies that ask patients to make choices about medications 
based on side effect profiles, studies have not explored the extent to which patients 
understand the benefit they get from commonly used drugs, such as daily preventive 
medications.  Improving medication prescribing and shared decision making between 
physicians and patients, particularly older adults with a high chronic disease burden, 
depends on patients’ ability to make informed decisions regarding medication benefits 
and risks. It is therefore critical that patients have some understanding of the magnitude 
of benefit conferred by their preventive medications, as well as of their underlying risk of 
important endpoints such as cardiovascular outcomes. Further research is needed to 
understand patients’ perceptions of their long-term risk of outcomes such as myocardial 
infarction and stroke, and to better characterize their perceptions of how well common 
preventive medications, such as aspirin, statins, and anti-hypertensives work to prevent 
these clinical outcomes.  
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Purpose 
 The purpose of this study is to examine older patients’ perceptions of their long 
term risk of cardiovascular outcomes, their perceptions of long-term benefit from 
common preventive medications (e.g., aspirin, statins, and anti-hypertensives) and to 
explore their medication adherence in relation to their general beliefs about medications 
and estimates of preventive medications’ benefit. 
 
Hypotheses 
We hypothesize 
1. Older patients on multiple medications have a poor understanding of their long-
term risk of cardiovascular outcomes such as myocardial infarction and stroke. 
2. Older patients have a poor understanding of the long-term benefit of commonly 
used preventive medications such as aspirin, statins, and anti-hypertensives, 
specifically that they have a poor understanding of the magnitude of the ability of 
the medication to prevent myocardial infarction or stroke.   
 
Specific Aims 
The aims of this study are 
1. To determine the extent to which older patients quantitatively understand their 
10-year risk of myocardial infarction and stroke. 
2. To determine the extent to which older patients quantitatively understand their 
10-year risk of myocardial infarction while on aspirin or statins, and their 10-year 
risk of stroke while on aspirin or anti-hypertensives, and thus to describe the 
magnitude of benefit patients believe is conferred by common preventive 
medications.  
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Methods 
 
Study Design 
 We performed a cross-sectional survey examining older adults’ ability to estimate 
medication benefit, followed by a chart review of enrolled participants to identify clinical 
characteristics, medication history, and adherence. A new instrument was developed for 
use in this study.  The study protocol was approved by the Human Studies 
Subcommittee at VA Connecticut Healthcare System and the Yale University School of 
Medicine Institutional Review Board. 
 The survey was developed by Elizabeth Wahl, with input from Joseph Agostini, 
MD, and Terri Fried, MD. Elizabeth Wahl wrote and submitted the protocol for IRB 
approval, recruited participants at the VA Connecticut Primary Care Center, 
administered the survey, created the Microsoft Access database, conducted chart 
reviews for all participants, and entered data. Data was analyzed by Elizabeth Wahl.  
 
Setting  
 We conducted the study and enrolled patients at the West Haven Veterans 
Affairs (VA) Primary Care Center from May to October 2007. The West Haven VA is part 
of the Veterans Affairs Connecticut Healthcare System, and includes a 191-bed inpatient 
facility and an ambulatory care center that registers more than 512,000 outpatient visits 
in West Haven and its clinics in New London, Stamford, Waterbury, Windham, Winsted 
and Danbury. The Primary Care Center consists of two medical firms; patients are 
randomly assigned to one firm for their medical care. 
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Participants  
 We enrolled a convenience sample of adults attending previously scheduled 
primary care or pharmacy education visits in each of the two medical firms. Participants 
were eligible for the study if they met the following inclusion criteria: age 65 years or 
older, community-dwelling, English-speaking, and taking 5 or more medications on a 
daily basis, including at least one of the drugs of interest (aspirin, a statin, or an anti-
hypertensive drug). A statin was defined as any HMG-coA reductase inhibitor drug (e.g., 
atorvastatin, simvastatin); an antihypertensive was defined as any of the five commonly 
prescribed classes of medications used for hypertension management, including ACE-
inhibitors, beta-blockers, calcium-channel blockers, diuretics, or centrally-acting agents.  
Over-the-counter vitamins, saline eye drops or nasal spray, and as needed (prn) 
medications were not counted as medications for the purposes of this study.  Exclusion 
criteria included a diagnosis of dementia in the medical record, participants documented 
as not competent to make their own medical decisions, and patients not receiving the 
majority of their medications through the VA system. 
 
Recruitment 
 Participants were recruited from May to October 2007. Eligible patients were 
identified on a daily to weekly basis from primary care provider and pharmacist 
schedules through the VA computerized medical records and appointments systems.  
Pharmacist visits emphasized diabetes education, anti-hypertensive medication regimen 
education, or medication review. Birth-date and active medication lists were used to 
confirm eligibility. The provider was notified of potential patients each day at the start of 
clinic and then invited patients to participate at the close of each visit. Patients who 
agreed to learn more about the study were then taken to a private room where the study 
was explained. If the patient agreed to the study, informed consent was obtained and the 
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survey completed. The survey instrument consisted of 43 items and took approximately 
15-20 minutes per participant to complete.  The interviewer read each question aloud to 
the participant and responses were recorded on a paper copy of the survey before being 
entered into a database created on Microsoft Access.  Once the survey was complete, a 
medical record review consisting of clinical and medication-related data was conducted, 
recorded on paper, and entered into the database. 
  
Measures 
 A survey instrument was developed for this study that included both novel and 
validated tools to assess three main outcomes: estimates of cardiovascular disease risk 
and medication benefit (Appendix 1), medication-related behaviors, including self-
reported adherence and experience with medication side effects, and attitudes and 
beliefs about medications.  Data collection also included a medical record review of all 
interviewed patients to obtain clinical and medication-related data.  
 Five demographics questions were recorded, including living situation (alone or 
with another person), current marital status, years of school completed, and ability to 
complete seven instrumental activities of daily living (IADL) (67), such as housework and 
handling finances. 
 Self-reported medication adherence was recorded using 4 questions from the 
Medication Adherence Scale developed by Morisky et al (68).  Participants were asked: 
“Do you ever forget to take your medications?”; “Are you careless at times about taking 
your medications?”; “When you feel better, do you sometimes stop taking your 
medications?”; “Sometimes, if you feel worse when you take your medication, do you 
stop taking it?” Those who answered no to all four questions were considered adherent; 
those who answered yes to at least one question were considered non-adherent.  This is 
the accepted definition of non-adherence used with the Morisky scale.  Participants were 
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also asked to report how many doses of medication they had missed in the past 2 days, 
if any.  Potential adverse effects related to medication use were elicited using questions 
about the experience of medication side effects with use of aspirin, statins, and anti-
hypertensives. Questions included: a) whether an adverse effect occurred (e.g., bleeding 
with aspirin); b) whether the drug was stopped; and c) whether the side effect was 
discussed with a doctor.  
 Attitudes and beliefs about medications were assessed using the Beliefs about 
Medicines Questionnaire (BMQ), developed and validated by Horne et al (69).  The 
BMQ consists of ten questions examining the extent to which participants agree or 
disagree with such statements as “My life depends on my medications.”  Responses 
were recorded on a 5 point Likert scale, ranging from 1 (strongly agree) to 5 (strongly 
disagree).  Participants were also asked whether they felt that the number of 
medications they were taking was about right, too many, or too few. 
 Participants’ estimates of cardiovascular disease risk and medication benefit 
were assessed by 6 novel questions developed for this survey.  We focused specifically 
on participants’ perceived risk of myocardial infarction and stroke, both at baseline (on 
no medications) and on preventive medications such as aspirin, statins, and anti-
hypertensives.  Perceived medication benefit was estimated by calculating the difference 
between participants’ risk estimates on and off medication.  Because the magnitude of 
preventive benefit conferred by these medications for myocardial infarction and stroke in 
a one-year period is extremely small, we focused on the ten-year risk of these outcomes.  
A large scale visual aid—a bar graph with answer choices at 0, 10, 25, 50, 75, and 
100—was developed and used with the questions, and a teaching module orienting 
participants to the visual aid preceded the questions.     
 To assess perceived disease risk and medication benefit, participants were 
asked, “For 100 people your age, who are just like you, with your exact same health 
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problems, a certain number of them will have a heart attack in the next ten years. Of 
those 100 people, who are your age with your exact same health problems, who aren’t 
taking any medication to prevent having a heart attack (like an aspirin or a statin), how 
many of them do you think will have a heart attack in the next ten years?”  Participants 
were asked to point to their answer choice on the bar graph.  Next, participants were 
asked, “Now, what if we put these [same] people on a daily aspirin [or statin, in the next 
question], now how many will have a myocardial infarction in the next 10 years?”  
Participants were again asked to select one of the six choices corresponding to their 
closest estimation.  The questions were repeated if participants required further thought.  
Participants were encouraged to answer even if they were not certain of the “exact” 
answer.  If a patient was unable to answer after prompting, then this was recorded. 
Participants were queried about each of the following scenarios: baseline MI risk without 
medication; MI risk on aspirin or on statin medications; baseline stroke risk without 
medication; and stroke risk on aspirin or anti-hypertensive medications.   
 In order to develop a visual aid that reflected an appropriate range of answer 
choices, Framingham data was used to calculate the 10-year risk for an “average” 75 
year-old male with type 2 diabetes, total cholesterol of 200, HDL of 45, blood pressure of 
130/80, and taking anti-hypertensives.  Data from primary prevention meta-analyses 
were used to calculate the benefits when patients take aspirin, statin, and anti-
hypertensives.  Based on Framingham data the ten-year risk of myocardial infarction for 
this “average” person (resembling the typical older male at VA Connecticut) falls within 
the range of 25-35% (70, 71), and the ten-year risk of stroke is between 20-35% (72, 
73).  These values are consistent even when varying certain characteristics.  When 
mean blood pressure is 170/80, the cardiovascular and cerebrovascular risk falls at the 
high end of the range; when diabetes is removed, the risk falls at the low end of the 
range.  For example, the 10-year risk of stroke is 17% for patients without diabetes and 
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23% for those with diabetes, for African American patients the risk is 22-28%, and for 
patients with atrial fibrillation or cardiovascular disease to the risk is 35%.  In the worst 
case scenario, LVH increases ten-year stroke risk to about 40%.   
 Clinical trial and meta-analysis data were used to derive the “average” 75-year 
old person’s 10-year risk of myocardial infarction on aspirin or statins, which both reduce 
the ten-year risk of myocardial infarction by about one-third to 15% (74-76).  For 
participants with diabetes, their 10-year risk of MI on medication may be closer to 20% 
since their starting risk is higher; however some data suggests that diabetic patients may 
derive greater benefit from aspirin for primary prevention of cardiovascular events.  For 
strokes, aspirin reduces the 10-year risk in high-risk patients by about one-quarter to 
15% (77).  Trials of anti-hypertensives in the elderly show that treatment of systolic 
hypertension in these participants (with any anti-hypertensive) resulted in a 37% 
reduction in stroke risk (78), so participants’ 10-year risk of MI on these medications is 
approximately 13%.  
 Given this range of “correct” answer choices, a bar graph was developed as a 
visual aid to depict a range of answer choices that captured the idea of “small risk,” 
“medium risk,” and “large risk,” from which people could choose. Based on current 
literature regarding chart literacy and numeracy, we chose to use a bar graph format 
with a 100-point scale to represent the number of people that could have a myocardial 
infarction or stroke in the next 10 years (64, 65). In our graph, answer options were 
placed at 0, 10, 25, 50, 75, and 100. These numbers were chosen because they span 
the range of small, medium, and large risk, but also reflect close “correct” answers to our 
questions (e.g., the ten-year risk of myocardial infarction/stroke is best correctly 
answered as “C” on the graph, corresponding to about 25; and the ten-year risk on any 
of the preventive medications is best answered as “B”, or about 10). All participants were 
given the same full-page enlargement of the bar graph with clear lettering in large (28  
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point) font to minimize problems due to visual impairment (see figure1 and full-size 
version in Appendix 1). 
 Because of concerns about numeracy and ability to read graphs, a teaching 
module was developed to familiarize participants with the numerical values on the bar 
graph prior to asking the questions about cardiovascular risk and medication benefit. 
Participants were shown the graph and told that it would be used to answer questions 
about chances of having a myocardial infarction and chances of having a stroke. They 
were oriented to the graph axes and then asked, “Can you show me the bar that best 
represents all 100 people? Can you show me the bar that best represents [x] people?” 
for all bar values on the graph. The questions were repeated until the participant could 
correctly identify all bar values.  Answers to the teaching module were not recorded (but 
no participants failed the teaching exercise).     
 Ascertaining participants’ risk estimates can be challenging because participants’ 
responses may be related to the sequence in which the questions were asked.  Prior 
investigators have demonstrated that the way in which questions are asked can drive 
choosing one answer over another (58, 59, 62).  To address this issue, we sequenced 
the questions so that baseline risk preceded risk on either medication, and questions 
were asked about myocardial infarction and then about stroke.  We varied whether 
participants were first asked about aspirin or the other medications to prevent either 
myocardial infarction or stroke for the first 20 surveys conducted; no patterns emerged, 
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Figure 1: Graph used by 
study participants for 
risk estimation 
questions. 
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and the ordering was not altered, although we cannot be certain that there were no 
framing effects.  
  
Chart review  
 Electronic medical records were also reviewed.  Domains included: twelve 
chronic medical conditions from a pre-selected list, number of medications the 
participant was taking at the time of interview, number of primary care and specific 
subspecialty (cardiology, endocrinology, nephrology, neurology) visits to an outpatient 
clinic in the year prior to the interview, and adherence to medications.  Adherence was 
defined using refill data (the percentage of actual versus expected refills for aspirin, 
statin, and anti-hypertensive medications during the year prior to the interview).  
  
Data Plan   
 Raw data from the survey and the chart review were collected using codes to 
protect participants’ confidentiality.  Data were collected on paper, stored in a locked 
cabinet, and then entered into a secure Microsoft ACCESS database. 
  
Data Analysis 
 Data were analyzed with univariate statistics to describe patient characteristics, 
demographics, and comorbidities, as well as the frequency with which patients estimated 
selected clinical outcomes when taking or not taking common preventive medications. 
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Results 
 
Study population 
 One hundred and fifty participants were recruited from the Primary Care Clinics 
at the VA Connecticut Healthcare System in West Haven between May and October 
2007.  Participants were drawn from regular primary care visits and pharmacy education 
visits for diabetic or hypertensive patients or patients on a complicated medication 
regimen.  Of 160 participants approached, 10 refused, and the final study sample and 
data analysis consisted of 150 participants. 
 Overall, the mean age of participants was 75.8 ± 6.0 years, all were male, and 19 
(12.7%) were non-white. Participants had a mean of 12.5 ± 3.1 years of education. 
Participants’ baseline characteristics are summarized in Table 1. Forty participants 
(27%) reported “fair” or “poor” health, and 31 (21%) participants reported difficulty with 1 
or more instrumental activities of daily living (IADLs). Participants had a mean of 3.7 ± 
1.2 of 12 pre-specified chronic medical conditions; 134 (89.9%) had hypertension, 83 
(55.7%) had ischemic heart disease, 113 (75.8%) had type 2 diabetes, 18 (12.1%) had a 
history of stroke, and 23 (15.4%) had a history of myocardial infarction. Participants had 
a mean of 2.9 ± 1.6 visits to their VA primary care provider in the past year, and a mean 
of 0.70 ± 1.4 visits to pertinent Internal Medicine subspecialties (Cardiology, 
Endocrinology, Nephrology, and Neurology).  
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Table 1: Baseline Characteristics of Study Participants (n=150)  
 
Characteristic Value 
 
Age, mean ±SD, years  
 
 
75.8 ± 6.0  
Non-white, No. (%) 
 
19 (12.7) 
Education, mean ±SD, years 
 
12.5 ± 3.1 
Living alone, No. (%) 
 
37 (24.7) 
Difficulty with ≥ 1 IADL* 
 
31 (20.6) 
Self-rated health, No. (%)  
     Excellent 10 (6.7) 
     Very Good 35 (23.3) 
     Good 65 (43.3) 
     Fair 34 (22.7) 
     Poor 
 
6 (4.0) 
 
Chronic medical conditions, No. (%)  
     Hypertension 134 (89.9) 
     Stroke 18 (12.1) 
     MI 23 (15.4) 
     Ischemic Heart Disease 83 (55.7) 
     Chronic Lung Disease (asthma/emphysema/COPD) 24 (16.1) 
     Diabetes 113 (75.8) 
     Arthritis 42 (28.2) 
     CHF 14 (9.4) 
     Cancer 38 (25.5) 
     Depression 35 (23.5) 
     Chronic Kidney Disease 29 (19.5) 
     Chronic Liver Disease 
 
3 (2.0) 
 
Chronic medical conditions reported from list above, mean ±SD
 
3.7 ± 1.2 
 
Primary care visits in last year, mean ±SD 2.9 ± 1.6 
 
Internal Medicine subspecialty visits in  
last year**, mean ±SD 
 
0.70 ± 1.4 
 
 
 
*IADLs are defined as Instrumental Activities of Daily Living as described in the text 
**Internal Medicine subspecialties here include Cardiology, Nephrology, Endocrinology, and Neurology 
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Medication characteristics and adherence 
 Participants were taking a mean of 9.8 ± 3.3 medications; 122 participants 
(81.3%) reported taking aspirin, 129 (86.6%) were taking a statin, and 145 (96.7%) 
patients were taking an anti-hypertensive medication. Two thirds of participants were 
taking all three medications.  13 (10.6%) of participants taking aspirin reported side 
effects, 6.2% of participants taking statins reported side effects, and 14.5% of 
participants taking anti-hypertensives reported side effects.  Both self-reported 
adherence data and actual refill data for statins and anti-hypertensives obtained by chart 
review were collected. Of all participants interviewed, 25 (19.5%) reported missing at 
least one dose of medication in the past two days, and 22 (17.3%) had a score of 
greater than one on the Medication Adherence scale, corresponding with poor self-
reported adherence (68). Based on refill data, 22 of 129 (17.3%) participants on statins 
and 17 of 145 (11.9%) participants on anti-hypertensives had <80% of expected refills in 
the past year.  Refill data were unable to be calculated for aspirin because most 
participants bought over-the-counter aspirin and therefore had no corresponding VA refill 
history.    
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Table 2: Medication Characteristics of Study Participants  
 
Characteristic  Value 
 
Active medications, mean ± SD  
 
 
9.8 ± 3.3 
Use of common preventive medications  
Aspirin, No. (%) 122 (81.3) 
Statin, No. (%) 129 (86.6) 
Anti-hypertensive, No (%) 145 (96.7) 
Aspirin, statins, and anti-hypertensives, No. (%) 
 
100 (66.7) 
Patients reporting side effects experienced on  
Aspirin, (n=122), No. (%) 13 (10.6) 
Statin, (n=129), No. (%) 8 (6.2) 
Anti-hypertensive (n=145), No. (%) 
 
21 (14.5) 
Self-reported general medication adherence  
Missed ≥1 dose in last 2 days, No. (%) 25 (19.5) 
Medication Adherence Score >1 (poor), No. (%) 
 
22 (14.7) 
 
Refill data from VA medication database, past year  
<80% expected statin refills (n=129), No. (%) 22 (17.3) 
<80% expected anti-hypertensive refills (n=145)* 
 
17 (11.9) 
 
* An average refill rate was calculated for patients taking >1 anti-hypertensive drug  
 
Medication beliefs  
 When asked about their perception of the number of medications they were 
taking, 111 (74%) of participants felt they were on ‘about the right number,’ while the 
remainder (25%) felt they were on ‘too many’ (see Table 3). Only one participant felt he 
needed to be on more medications. In addition, participants answered questions from 
the Beliefs about Medications Questionnaire (69) to explore attitudes towards medication 
necessity and medication harm. Medication was felt to be important for preserving health 
and maintaining well-being, with participants’ mean responses ranging from 1.7 to 2.3 on 
a 5 point Likert scale (1=strongly agree, 5= strongly disagree) for ‘medication necessity’ 
domains. Patients were more ambivalent (expressed less agreement) towards 
statements exploring the extent to which medication is harmful, burdensome, or 
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addictive, with mean responses of 3.1 to 3.6 on the 5-point scale for ‘medication 
concern’ domains.  
 
Table 3: Participants’ Beliefs about Medications  
 
Characteristic  Value 
 
Perceived number of medications   
Too many, No. (%) 37 (24.7) 
About right, No. (%) 111 (74.0) 
Too few, No. (%) 1 (0.7) 
Don’t know, No. (%) 1 (0.7) 
 
Beliefs about Medicines Questionnaire (69)  
   Necessity Domains, mean ± SD  
My health right now depends on my medicines 1.7 ± 0.6  
My life would be impossible without my medicines 2.3 ± 1.0 
Without my medicines, I would be very ill 2.1 ± 0.9 
My health in the future depends on my medicines 1.9 ± 0.7 
My medicines protect me from becoming worse 
 
1.9 ± 0.6 
 
   Concern Domains, mean ± SD  
Having to take medicines worries me 3.4 ± 1.0 
I sometimes worry about the long-term effects of my 
medicines 3.1 ± 1.2 
My medicines are a mystery to me 3.3 ± 1.2 
My medicines disrupt my life 3.6 ± 1.0 
I sometimes worry about becoming too dependent on my 
medicines 
 
3.4 ± 1.1 
 
 
* Participant responses based on a 5-point Likert scale (1=strongly agree and 5=strongly 
disagree) 
 
 
Estimating Risk of Myocardial infarction and Stroke  
 Based on Framingham data, the 10-year risk of myocardial infarction for this 
population is approximately 25-30% (70, 71).  Participants were asked to estimate their 
10-year risk of myocardial infarction (MI risk) while on no medications, and were 
presented with a bar graph with answer choices at 0, 10, 25, 50, 75, and 100.  Of 150 
participants asked, 17 (11%) were able to accurately estimate their MI risk (Table 4). 
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Nearly all overestimated their risk; 130 (87%) participants guessed that their risk was 
50% or more, and 72 (48%) participants guessed their MI risk was 75 or 100%. Two 
participants underestimated their risk, guessing it was 0 or 10%, and one subject 
declined to guess.  
 
Table 4: Estimating 10-year risk of MI and CVA On and Off of Preventive Medications*  
 
 Participants who estimated their 10-year risk at. . . No. (%)  Total 
 
0 10 25 50 75 100 
 
10 year risk of MI         
     No medication 1 (1) 1 (1) 17 (11) 58 (39) 37 (25) 35 (23) 149
     Aspirin 3 (2) 20 (14) 54 (36) 53 (36) 16 (11) 2 (1) 148
     Statin 3 (2) 25 (17) 54 (37) 47 (32) 15 (10) 3 (2) 147
       
10 year risk of CVA       
     No medication 0 (0) 2 (1) 19 (13) 38 (26) 57 (38) 33 (22) 149
     Aspirin 0 (0) 22 (15) 54 (37) 52 (35) 18 (12) 1 (1) 147
     Anti-hypertensive 4 (3) 38 (26) 48 (32) 39 (26) 18 (12) 1 (1) 148
 
* Data were missing from 3 patients who refused to guess in some or all scenarios.  Shaded 
boxes indicate the most accurate answer for the population. 
 
 
 
 Framingham data project the 10-year risk of stroke at approximately 20-25% 
depending on presence or absence of diabetes (72). Nineteen participants (13%) were 
able to accurately estimate their CVA risk, while 128 (86%) guessed that their risk was 
50% or more (Table 4). Overall, participants estimated a higher baseline risk of CVA 
than of MI, with 90 participants (60%) estimating their 10-year CVA risk was 75 or 100%. 
No subject thought CVA risk was zero, two underestimated risk at 10%, and one subject 
declined to guess. 
 
   
 
26
Risk of Myocardial infarction on Preventive Medications  
 Data from trials looking at aspirin and primary prevention of myocardial 
infarctions show that daily aspirin should reduce the 10-year risk of MI by about a third, 
which corresponds to about 15% for this population, or a ‘correct’ answer of about 10% 
on the bar graph (74).  When asked to estimate 10-year MI risk while taking daily aspirin, 
20 participants (14%) chose the ‘correct’ answer, although this does not take into 
consideration the accuracy of their baseline risk estimate (Table 4). One hundred 
twenty-five (84%) participants overestimated their risk of MI on aspirin, guessing it to be 
25% or higher. Eighteen (12%) participants guessed that their risk was as high as 75 or 
100%; 3 (2%) participants underestimated MI risk on aspirin, and two participants 
declined to guess.  
 Statin prevention benefit is comparable to that of aspirin, with a reduction in the 
10 year risk of MI by about one-third (75, 76), also corresponding to a ‘correct’ answer of 
10% on our graph. Participants’ estimates of MI risk while taking statins were similar to 
their estimates of MI risk while taking aspirin.  Twenty-five (17%) participants ‘correctly’ 
estimated the 10-year risk of MI on statins (Table 4). One hundred eighteen (81%) 
participants overestimated their risk of MI on statins, with 17 (12%) of participants 
estimating it to be as high as 75 or 100%. Two participants (1%) felt that taking a statin 
eliminated the risk of MI entirely, while 3 participants declined to guess.     
 
Risk of stroke on preventive medications  
 Daily aspirin should reduce the 10-year risk of CVA by about a third, 
corresponding to about 15% for this population and a ‘correct’ answer of 10% on our 
graph (77).  Twenty-two (15%) participants ‘correctly’ estimated their risk of CVA on 
aspirin, while 125 (85%) participants overestimated their risk (Table 4). Nineteen (13%) 
participants guessed their risk was as high as 75 or 100%. No participants felt that 
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aspirin brought their risk of CVA to zero, and 3 participants declined to guess for this 
section.        
 Anti-hypertensives should reduce the 10-year risk of CVA by about 37% to about 
15% in this population, or a ‘correct’ answer closest to the 10% choice on our graph (78).  
Thirty-eight participants (26%) chose the ‘correct’ estimate of CVA risk on anti-
hypertensive medication (Table 4). One hundred six (71%) participants overestimated 
their CVA risk, with 19 (13%) participants estimating risk to be as high as 75 or 100%. 
Four participants (3%) felt that anti-hypertensives eliminated CVA risk altogether, and 2 
participants declined to guess.  
 
Preventive Medication Benefit 
 In addition to examining how accurately participants were able to estimate their 
risk of myocardial infarction and stroke both on and off of preventive medications, we 
also examined the number of participants who accurately estimated the magnitude by 
which aspirin and statins would reduce MI risk, and the magnitude by which aspirin and 
anti-hypertensives would reduce CVA risk. Results are summarized in TABLE 5(a-d).  
 Most participants estimated that medication reduced the risk of MI (TABLE 5a, 
5b), although there was variability in terms of how much participants felt medication 
decreased risk.  No participants thought aspirin decreased the risk of MI from 100 to 
zero, but two participants thought statins could decrease MI risk to this extent.  One 
participant thought aspirin increased risk of MI and three thought the same of statins.  
Few participants estimated the ‘correct’ answer (that MI risk is around 25 and drops to 
around 10 on either medication)--overall, 15 (10%) participants made accurate guesses 
about aspirin and 10 (7%) participants made accurate guesses about statins.  
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TABLE 5a-d: Participants’ Estimation of Risk on Preventive Medications, Taking 
Into Consideration their Initial Risk Estimation   
 
Darkest boxes represent participants who felt that medication did not change their risk of 
outcome; each lighter shade represents those who felt that aspirin changed their risk by one (or 
two, three, or four) bars on the graph. 
 
Table 5a. Participants’ Estimate of MI Risk at Baseline and on Aspirin (N=148) 
Participants’ 
Estimate of 
Baseline MI Risk 
Participants’ Estimate of MI Risk on Aspirin, No. (%) TOTAL
 
 100 75 50 25 10 0  
100 2 (1.4) 10 (6.8) 17 (11.5) 5 (3.4) 0 0 34
75 0  5 (3.4) 21 (14.2) 9 (6.1) 1 (0.7) 1 (0.7) 37
50 0 1 (0.7) 15 (10.1) 38 (25.7) 3 (2.0) 1 (0.7) 58
25 0 0 0 2 (1.4) 15 (10.1) 0 17
10 0 0 0 0 1 (0.7) 0 1
0 0 0 0 0 0 1 (0.7) 1
 
TOTAL 2 16 53 54 20 3 148
 
 
 
Table 5b. Participants’ Estimate of MI Risk at Baseline and on Statins (N=147) 
Participants’ 
Estimate of 
Baseline MI Risk 
Participants’ Estimate of MI Risk on Statins, No. (%) TOTAL
 
 100 75 50 25 10 0  
100 3 (2.0) 8 (5.4) 13 (8.8)  9 (6.1) 1 (0.7) 1 (0.7) 35
75 0 5 (3.4) 19 (12.9) 12 (8.2) 1 (0.7) 0 37
50 0 2 (1.4) 14 (9.5) 27 (18.4) 12 (8.2) 1 (0.7) 56
25 0 0 1 (0.7) 6 (4.1) 10 (6.8) 0 17
10 0 0 0 0 1 (0.7) 0 1
0 0 0 0 0 0 1 (0.7) 1
 
TOTAL 3 15 47 54 25 3 147
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Table 5c. Participants’ Estimate of CVA Risk at Baseline and on Aspirin (N=147) 
Participants’ 
Estimate of 
Baseline CVA 
Risk 
Participants’ Estimate of CVA Risk on Aspirin, No. (%) TOTAL
 
 100 75 50 25 10 0  
100 1 (0.7) 9 (6.1) 17 (11.6) 6 (4.1) 0 0 33
75 0 8 (5.4) 31 (21.1) 16 (10.9) 2 (1.4) 0 57
50 0 1 (0.7) 4 (2.7) 28 (19.0) 5 (3.4) 0 38
25 0 0 0 4 (2.7) 14 (9.5) 0 18
10 0 0 0 0 1 (0.7) 0 1
0 0 0 0 0 0 0 0
 
TOTAL 1 18 52 54 22 0 147
 
 
Table 5d. Participants’ Estimate of CVA Risk at Baseline and on Anti-hypertensives 
(N=148) 
Participants’ 
Estimate of 
Baseline CVA 
Risk 
Participants’ Estimate of CVA Risk on Anti-hypertensives, 
No. (%) 
TOTAL
 
 100 75 50 25 10 0  
100 1 (0.7) 7 (4.7) 9 (6.1) 9 (6.1) 5 (3.4) 2 (1.4) 33
75 0 10 (6.8) 19 (12.8) 19 (12.8) 9 (6.1) 0 57
50 0 1 (0.7) 11 (7.4) 16 (10.8) 9 (6.1) 1 (0.7) 38
25 0 0 0 4 (2.7) 14 (9.5) 1 (0.7) 19
10 0 0 0 0 1 (0.7) 0 1
0 0 0 0 0 0 0 0
 
TOTAL 1 18 39 48 38 4 148
 
 
 
 Most participants estimated that medication reduced the risk of CVA (TABLE 5c, 
5c), although there was variability in terms of how much participants felt medication 
decreased risk.  No participants thought aspirin decreased the risk of CVA from 100 to 
zero, but four participants thought anti-hypertensives could decrease CVA risk to this 
   
 
30
extent, and one participant thought aspirin and anti-hypertensives would increase risk of 
CVA.  Few participants estimated the ‘correct’ answer (that CVA risk is around 25 and 
drops to around 10 on either medication)--overall, 14 (10%) participants made accurate 
guesses about aspirin and anti-hypertensives.  
 
Magnitude of benefit  
 Table 6 summarizes the extent to which people felt that aspirin, statins, and anti-
hypertensives increased or decreased their risk of myocardial infarction and stroke, 
regardless of how accurate their estimates were. Because participants were forced into 
choosing specific values on a bar graph (0, 10, 25, etc.), moving up or down one bar 
was considered to represent one ‘level’ of change (whether that was from 100 to 75 or 
25 to 10).  
 
TABLE 6: Participants’ Perceptions of Medication Benefits from Preventive 
Medications by Level of Change  
 
Medication and 
Outcome  
Participants’ Estimate of Change in Risk on Medication, No. (%)  
 
Total 
 
 
Did not 
change  
risk* 
↓ risk by 
1 level 
↓ risk by 
2 levels 
↓ risk by 
3 levels 
↓ risk by 
4 levels 
↓ risk by 
5 levels 
 
Aspirin for  
MI prevention 26 (17.7) 84 (56.8) 29 (19.6) 7 (4.7) 1 (0.7) 0 148
Statins for  
MI prevention 30 (20.4) 64 (43.5) 37 (25.2) 11 (7.5) 1 (0.7) 1 (0.7) 147
Aspirin for  
CVA prevention 18 (12.2) 82 (55.8) 38 (25.9) 8 (5.4) 0 0 147
Anti-
hypertensives  
for CVA 
prevention 
27 (18.2) 56 (37.8) 38 (25.7) 19 (12.8) 5 (3.4) 2 (1.4) 148
*A small number of participants felt that taking the medication increased their risk of having an MI 
or a CVA – 1 in the ASA/MI group, 3 in the statins/MI group, 1 in the aspirin/CVA group, and 1 in 
the anti-hypertensives/CVA group. 
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Approximately half of participants thought that each medication decreased their 
risk by one level, or the correct amount: 84 (57%) participants thought aspirin lowered MI 
risk by one bar, 64 (43.5%) participants thought statins lowered MI risk one bar, 82 
(56%) participants thought aspirin lowered CVA risk one bar, and 56 (38%) participants 
thought anti-hypertensives lowered CVA risk one bar.  The remaining participants both 
over- and under-estimated the prevention benefit of each medication.  36 (25%) 
participants felt that aspirin decreased the risk of MI by two or more bars on the graph, 
while 50 (33%) participants felt that statins decreased the MI risk by at least that amount.  
Similarly, 46 (31%) participants felt that aspirin decreased CVA risk by at least two bars, 
while 64 (43%) felt that anti-hypertensives decreased CVA risk by two or more bars.    
 A substantial number of participants felt that preventive medications did not 
change their risk of MI or CVA. Twenty-six participants (18%) felt that taking a daily 
aspirin did not change their 10-year MI risk, and 30 participants (20%) felt that taking a 
daily statin did not change that risk. Eighteen participants (12%) guessed that taking a 
daily aspirin did not change their 10-year CVA risk, while 27 (18%) guessed that anti-
hypertensives would not change that risk.   
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Discussion 
 
 Previous research with older adults in the ambulatory setting has suggested that 
patients have limited knowledge about the indications, dosing schedules, and side 
effects of their medications (35, 36).  Because impaired medication knowledge has been 
shown to correlate with morbidity and mortality in the elderly (41), we sought to 
quantitatively assess the extent to which an older population understands their 10-year 
risk of myocardial infarction or stroke, and their perceptions of the ability of medications 
to modify this risk.  We found that most patients have limited knowledge both about their 
10-year risk of cardiovascular events such as myocardial infarction and stroke, as well 
as an inaccurate sense of how well common medications work to prevent these 
outcomes.  Significant numbers of participants both over and underestimate their 
cardiovascular risk, as well as the ability of medications to provide benefit.  Our data 
suggest that current efforts by clinicians to educate these patients have not adequately 
addressed participants’ knowledge of cardiovascular risk and preventive medication 
efficacy, particularly since making informed decisions about medications requires that 
patients make accurate predictions about disease outcome and medication benefit and 
risk.   
  
Medication Adherence and Medication Beliefs 
 Studies of statin adherence in the elderly from the previous decade suggested 
that adherence rates in the Medicare population drop as low as 42% after two years 
(79), although other studies suggest that rates may be somewhat higher (80).  In our 
study, statin adherence rates were higher.  About 80% of participants both had high self-
reported adherence to medications and were found to be adherent to statins based on 
refill data, with only 8% reporting medication side effects. Of note, a recent study 
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examining factors that determine statin adherence for primary prevention of myocardial 
infarction among veterans found that low perceived risk was one factor associated with 
non-adherence (81).  Our findings indirectly support this result, as our study population 
both perceived their risk of myocardial infarction to be high and had a higher adherence 
rate. Similarly, earlier studies of anti-hypertensive use also found low adherence rates in 
the elderly, although some studies have shown older age to be associated with improved 
adherence (82). Our study describes much higher rates of adherence (80%) to anti-
hypertensives, both in terms of self-reported general medication adherence and specific 
refill data.  Of note, we looked both at general medication adherence by self report 
(using the Morisky scale as well as self-reported medications missed in the past 2 days) 
and specific medication adherence by refill data.  Refill data from VA Connecticut specify 
when medication is mailed to or picked up by the patient rather than whether the 
participant actually takes the medication.  This may account for higher adherence levels 
in the population, although this technique has been used by other VA-based adherence 
studies. 
 Other studies that have used the Beliefs About Medicines Questionnaire (BMQ) 
have described a positive correlation between agreement with Medication Necessity 
domains and adherence, and a negative correlation between agreement with Medication 
Concern Domains and adherence (43). While our study did not specifically relate 
participants’ BMQ responses to their adherence rates, our finding that participants 
agreed strongly with Medication Necessity domains correlates with our findings of high 
adherence rates observed in this population.  In our study, the BMQ also served as a 
means of characterizing this populations’ attitude towards medications. Most participants 
agreed strongly or very strongly with statements that medication in general could prevent 
them from becoming sicker, and that their well-being and life depended on their 
medications.  It is possible that participants may have felt uncomfortable disagreeing 
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with questions about medication benefit, perceiving that the interviewer expected them 
to agree, although they did express ambivalence or disagree with the series of 
statements designed to elicit perceptions of medication harm. These findings may reflect 
a belief system of this particular generation or social group (veterans) that places great 
faith in their physicians, and support use of the BMQ to better understand attitudes 
toward medication held by patients of different ages.   
 
Estimating Risk of Myocardial Infarction and Stroke  
 The finding that older adults do not accurately estimate their 10-year risk of 
myocardial infarction and stroke is not surprising, given that people have difficulty 
estimating events with small probabilities. Several studies suggest that when asked to 
estimate events with low probabilities, patients either dramatically over or underestimate 
these outcomes (53, 63, 83).  In addition, several qualitative studies have described an  
‘optimistic bias’ among participants estimating their cardiovascular risk, in that they 
perceive their risk level to be much lower than it actually is (84, 85).  In contrast, our 
findings that participants largely overestimated their risk of MI and stroke are consistent 
with several studies that asked patients to estimate their cardiovascular disease risk  
(86, 87).  In a study by Frijling et al., ambulatory patients with hypertension or diabetes in 
the Netherlands were asked to estimate their 10-year risk of MI and stroke using an 
analogue scale.  The majority of patients overestimated their risk of these outcomes, 
with half of patients overestimating by more than 20%, and older patients especially 
estimating a higher risk.     
 There are several possible explanations for our findings that patients 
overestimate cardiovascular risk.  First, participants may have had no idea of their actual 
risk of myocardial infarction or stroke, and may have selected the least extreme answer 
(50%), which is an overestimate by coincidence.  Alternatively, for the small but 
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significant percentage of participants who had prior history of myocardial infarction 
(15.4%) or stroke (12.1%), their risk levels are truly higher than other patients, and their 
perception of risk may have been skewed to the high end of the choices.  Third, many 
participants were recruited following education visits with pharmacists regarding their 
chronic conditions such as diabetes and hypertension. If participants received frequent 
counseling about the importance of taking diabetes and blood pressure medications, this 
frequent emphasis may have positively distorted their perceived risk of cardiovascular 
outcomes.  Finally, many participants anecdotally referenced friends or family members 
who had experienced myocardial infarction or stroke as a reason why they believed their 
risk of these outcomes was quite high.  Fear of loss of function may have contributed to 
an increased perceived risk of stroke, in particular. 
   Notably, some participants stated they had absolutely no idea of their risk, and 
felt it was their doctor’s job to know their risk and decide about appropriate medications.  
We know from prior studies examining older patients’ preferences about participation in 
medication-related decision-making that not all patients want to be included in the 
process (25).  However, strategies to enhance patient knowledge may improve patient 
confidence and willingness to be involved in conversations about treatment decisions.    
Thus, improving education and knowledge about long term risk of myocardial infarction 
and stroke may be useful for patients taking multiple medications and allow them to think 
about treatment priorities.  To that point, a recent study suggests that improving patients’ 
knowledge of their coronary risk may even improve medication adherence and treatment 
efficacy (88). 
 We do not suggest that participants’ overestimation of the baseline risk of 
myocardial infarction or stroke is purely problematic.  In fact, there may be benefits to 
patients believing these risks to be higher than they actually are. A greater perceived risk 
of myocardial infarction and stroke may create incentive to take preventive medications, 
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which have lower adherence rates than medications which provide symptom relief (81), 
and can minimize the likelihood of costly disease sequelae.    
 
Perceived Medication Benefit for Myocardial Infarction and Stroke Prevention 
 As hypothesized, a significant number of participants did a poor job of estimating 
the ability of aspirin and statins to reduce their 10-year risk of myocardial infarction, both 
under- and over-estimating the effectiveness of these medications.  Prior studies have 
demonstrated variability in patients’ expectations of preventive medication benefit (89, 
90).  A study by Llewellyn-Thomas and others found that 28-38% of ambulatory patients 
expected greater benefit than could be provided by their anti-hypertensives and lipid-
lowering agents.  Similarly, our study found that 33-43% of participants overestimated 
the benefit provided by these medications. This study supports our findings that people 
expect a higher level of benefit than can be provided by preventive medication. Of note, 
the mean age in our study was 20 years older than in the study by Llewellyn-Thomas, 
possibly suggesting that the expectation of benefit increases with age.  In contrast, 
studies exploring reasons behind statin non-adherence have found that patients both 
expect lower levels of benefit from these medications and have lower levels of perceived 
cardiovascular risk (89).  The reason for these discrepancies is unclear, but suggests 
that in general, patients do not have a good understanding of the benefit provided by 
their medications.      
 Many studies about medication benefit reported in the literature have focused on 
understanding risk-benefit trade-offs that patients are willing to make for a certain level 
of medication benefit (28), (90).  These studies demonstrate that patients generally are 
willing to take daily preventive medication as the absolute risk reduction provided by 
those medication increases.  Because so many participants in our study overestimated 
preventive medication benefit, it is possible that they may be more willing to tolerate 
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adverse medication effects and regular healthcare interactions given their high 
expectations.   
 On the other end of the spectrum, one in five participants in our study felt that 
medications did not reduce the risk of myocardial infarction or stroke.  Poor perceived 
medication efficacy is a risk factor for non-adherence and also has important 
implications for shared decision-making regarding medication use.  Patients who do not 
perceive any benefit from medications (that truly do have potential benefit) have limited 
ability to make informed decisions.  The framework of shared decision-making between 
patient and physician is predicated on the fact that both parties take into account the 
best available evidence for risks and benefits of treatment.  These findings—that 
participants both over- and under-estimate the potential benefit provided by their 
preventive medications—suggest that clinicians still have much work to do in educating 
patients about the role of medications.   
 Several qualitative studies have explored beliefs and common misconceptions 
that older patients have about their medications, such as the idea that missing a statin 
dose will result in a myocardial infarction the following day, or the more common notion 
that preventive medications are ineffective (42, 46).  However, participants in this study 
exhibited less extreme, more nuanced thinking.  Of the nearly 25% of participants who 
thought their 10 year risk of MI was 100%, none thought aspirin would drop that risk to 
zero, and only one thought a statin reduced the risk by that degree.  Of similar numbers 
of participants who thought their 10 year risk of stroke was 100%, none thought aspirin 
could drop their risk to zero, and only two thought an anti-hypertensive could reduce it by 
that degree.  The fact that patients are able to appreciate risk in these terms should 
inform and improve the way information is conveyed during a clinical encounter.  
 Several participants estimated that risk of myocardial infarction increased while 
on preventive medication. It is possible that these participants either did not understand 
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the initial question, or that they truly believe the medication does cause harm. While it is 
certainly possible that participants believe the medication to be harmful, the latter seems 
more likely, particularly since no person expressed this sentiment in the medication 
beliefs section of the survey.  In addition, some participants commented (while 
answering the survey questions) that other factors, in addition to or instead of 
medication, modified their risk, particularly lifestyle factors such as diet, exercise, and 
smoking.  Future studies could address the perceived benefit of preventive medication 
as compared to lifestyle interventions.    
 Participants’ responses to the medication beliefs questionnaire suggests that the 
majority of felt that taking medication in general was beneficial for health and could 
prevent their health from getting worse.  It was therefore unexpected that such 
significant numbers of participants felt that these medications had no beneficial effect.  
The discrepancy between the qualitative results from the medication beliefs 
questionnaire and the quantitative results of the risk estimation portion of the survey hint 
that medication beliefs and perceived benefits of medication are distinct concepts, and 
that to maximize patient understanding, each needs to be addressed in the clinical 
encounter.   
 
Implications for Prescribing and Medication Decision-Making 
 While previous studies have addressed patients’ estimates of their 
cardiovascular disease risk, to our knowledge, this is one of few studies to quantitatively 
assess patients’ perceptions of preventive medication benefit.  Our study confirms that 
older patients with multiple chronic conditions taking multiple medications both over- and 
under-estimated the ability of their preventive medications to prevent myocardial 
infarction and stroke.  Patients who feel that medication provides no preventive benefit 
may be more likely to be non-adhererent with medication.  In addition, patients who 
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over-estimate the ability of medication to prevent outcomes may not be forthcoming 
about reporting medication side effects.  These findings have important implications for 
patient education and the way in which doctors and physicians interact to arrive at 
decisions about medications.   
 It is particularly important for older patients who have a high medication burden, 
a high risk of adverse effects, and cost burden to be able to make choices about their 
medications.  It is also important for these patients to be able to communicate priorities 
to their physicians to the extent that they are able and interested in doing so.  In order to 
make informed choices about medications, however, patients need to understand the 
risk of common health outcomes (such as myocardial infarction or stroke), and how 
effectively medications prescribed to prevent these outcomes are expected to work.  
Since patients may prioritize health outcomes differently, prescribing medications with 
these outcomes in mind requires that clinicians understand patient preferences (25-27).   
 For patients taking medication to prevent cardiovascular outcomes such as 
myocardial infarction or stroke, patient education should focus on informing patients both 
about cardiovascular risk and about risk reduction provided by preventive medications 
over time.  Decision aids or graphical representations may be helpful in communicating 
cardiovascular risk (91).  Physicians can use graphs as one means of communicating 
the absolute risk reduction provided by common medications, which may be useful in 
helping patients better understand the potential benefit medications can provide.   
   
Strengths and Limitations 
  Strengths of this study include the sample size, which provides a representative 
sample of older males with multiple chronic conditions who take multiple medications. 
Because the study setting is a Veterans Administration Hospital, the participants were 
veterans who had regular and frequent visits to general medicine and subspecialty care 
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physicians, in addition to low-cost (or free) prescription drug coverage.  For these 
reasons, lack of healthcare access and medication coverage likely do not play a large 
role in why our participants’ might answer health and medication questions incorrectly 
(compared to participants with little insurance or no primary care physician).  This study 
is also the first study of which we are aware to look at older adults’ understanding of 
medication benefit of commonly prescribed drugs. Earlier studies have focused on 
medication knowledge, medication literacy, and ability to understand risk. Our study 
therefore adds to this literature in these domains and provides relevant preliminary data 
to explore additional questions related to medication benefit in other diverse older patient 
populations.  Although several previous studies have explored physicians’ ability to 
estimate cardiovascular disease risk (56, 57), our study focused primarily on patients’ 
understanding of these outcomes.  Finally, this study explored the benefits of common 
preventive medications using a standardized method, developed a visual risk 
assessment tool based on previous health risk literature pertinent to older adults, and 
employed a clinically relevant context for older males by incorporating clinical conditions 
such as hypertension, myocardial infarction, and stroke that are common in this 
population. 
  The aim of our study was to describe patients’ estimates of how well common 
medications work to prevent myocardial infarction and stroke. We did not expect patients 
to know their exact risk; rather, we wanted to understand whether they thought their risk 
was nearly zero, small, medium, high, or nearly 100%. For this reason, we selected 
values on a bar graph that do not correlate with any one patient’s exact risk. 
Furthermore we did not calculate the exact risk for each individual; rather we calculated 
an average risk for the population surveyed. As a result, a small number of these 
participants likely had a higher risk than we estimated for the entire cohort (because 
75% of the sample had diabetes, 15% had a history of prior MI, and 12% had a history of 
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prior stroke). However, this does not change the fact that significant numbers of 
participants believed medications had no benefit, nor does it discount the finding that 
many participants have a distorted sense of medications benefit.  
 All participants enrolled in the study were male veterans from the Korean War or 
World War II. This generation has a unique character and set of beliefs, namely that they 
generally prefer physicians to be responsible for their health-related decision making 
(25, 92).  In addition, older persons may have less interaction with newer sources of 
healthcare information, such as the internet, compared to younger persons (93).  And, 
although the majority of the aging population is women, women were not enrolled in this 
study. It is unclear if women would have similar risk estimates, or would respond 
differently to questions about medication beliefs.  Finally, although this study had a 
robust sample size to characterize participants’ perceived risk of myocardial infarction 
and stroke both on and off medications, the size was not large enough to look for an 
association between medication knowledge and adherence.  
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Summary 
  
 The majority of participants in this study significantly overestimated their risk of 
myocardial infarction and stroke, as well as the risk of these outcomes while on aspirin, 
statins, and anti-hypertensive medications. This suggests that patients do not have a 
good understanding of the long-term risk of these outcomes.  A very small number of 
participants were able to accurately estimate their 10-year risk of myocardial infarction 
and stroke, and although by Framingham data these risks are similar, more participants 
thought their 10-year risk of stroke was higher than their risk of myocardial infarction.  
More than three quarters of participants felt that medications were able to reduce their 
risk to some degree, and almost no participants thought that medication could eliminate 
risk altogether; however, 25-44% of participants dramatically overestimated the ability of 
medications to reduce their risk.  In addition, one in five participants felt that aspirins, 
statins, and anti-hypertensives did not modify their long-term risk of myocardial infarction 
or stroke.  While overestimation of medication benefit may not be harmful to participants, 
the misperception may inappropriately influence patients’ decisions about medications 
and treatment priorities.  Because participants agreed strongly with statements that 
medications are important for maintaining health and were ambivalent towards 
statements that medications could be harmful, it was surprising that so many participants 
indicated that medication did not modify risk, suggesting a discrepancy between 
medication beliefs and medication knowledge.  Our data suggest the need for improved 
communication between patients and physicians concerning long-term cardiovascular 
risk and medication benefit in patients with significant comorbidities who are taking 
multiple medications.  Visual risk communication tools may be one means to improve the 
quality of these conversations.
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APPENDIX 1: Survey Instrument  
BELIEFS ABOUT MEDICINES QUESTIONNAIRE (BMQ) 
 
Instruction: For the first part of the survey, I’m going to read you some statements that other 
people have made about their medicines, and I want to know how much you agree or disagree 
with them.  Let’s use this scale (where 1 means that you strongly agree with the statement, and 5 
means that you strongly disagree with it). I want you to point to the answer that best shows how 
you feel. There aren’t any right or wrong answers; I just want to know what you think.  
 
1-strongly agree 
2-agree 
3-neither agree nor disagree 
4-disagree 
5-strongly disagree 
7-ref 
8-dk 
9-na 
 
1 My health right now depends on my medicines   1     2     3     4     5    
 
 
2 Having to take medicines worries me    1     2     3     4     5     
 
3 My life would be impossible without my medicines  1     2     3     4     5     
 
4 Without my medicines I would be very ill    1     2     3     4     5    
 
 
5 I sometimes worry about the long-term effects of my medicines 1     2     3     4     5    
 
 
6 My medicines are a mystery to me    1     2     3     4     5    
 
 
7 My health in the future depends on my medicines  1     2     3     4     5    
 
 
8 My medicines disrupt my life     1     2     3     4     5    
 
 
9 I sometimes worry about becoming too dependent  1     2     3     4     5     
 on my medicines. 
 
 
10 My medicines protect me from becoming worse    1     2     3     4     5    
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TEACHING EXERCISE [no recorded answers] 
 
Instruction: Great. Now we are going to get oriented to this graph, and then we are going to use 
it to answer some questions about heart attacks and strokes. Along the left side of the graph, 
there are 100 people. Along the bottom, there are six bars that represent different numbers of 
people. Choice A shows almost no people at all. Choice B shows about 10 people. Choice C 
shows about 25 people. Choice D shows about 50 people. Choice E shows about 75 people, and 
choice F shows all 100 people.   
 
Can you point to the bar that shows all 100 people? 
 
Now can you point to the bar that shows 0 people? 
 
Now point to the bar that shows 50 people. 
 
And the bar that shows closest to 15 people? 
 
And the 2 bars that show greater than 50 people?  
 
Good job. Do you have any questions about this graph before we move on? 
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HEART ATTACK AND STROKE PREVENTION QUESTIONS (PQ) 
 
Instructions: Now we are going to use the graph we just went over to talk about the chances of 
having a heart attack or a stroke, and to think about how much some of the medications you take 
change the chances of those events. It doesn’t matter if you know the right answer! I just want 
you to think about the question and make a good guess. Please stop me at any time if you have 
questions.  
 
7-ref 
8-dk 
9-na 
 
11 First we’re going to talk about heart attacks. Of 100 
people who are your age with your same health problems, 
a certain number of these people will have a heart attack 
in the next 10 years. So for 100 people who are your age 
and your same health problems, but they are not taking 
any medications to prevent having a heart attack (like 
Aspirin or a cholesterol medication like Lipitor), how 
many of them do you think will have a heart attack in the 
next 10 years?    
 
(Let me repeat that again [etc.] So you are saying that x 
people with your same health problems will have a heart 
attack in the next 10 years?)  
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12 The people we just talked about were not taking medicine 
to prevent heart attacks. Now, let’s talk about people who 
are taking aspirin. Again, these are 100 people who are 
just like you in terms of your health, and they are taking a 
daily aspirin to prevent having a heart attack. Using the 
choices on the graph, how many of these 100 people do 
you think will have a heart attack in the next 10 years? 
(Choose the bar that is closest to what you think the 
answer is)  
 
(Do you think that taking aspirin will change the number of 
people who will have a heart attack? Will the number go up or 
down? How much will it go up or down? Remember, you can 
choose any answer). You are saying (x) people taking 
aspirin will have a heart attack in the next 10 years? 
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13 Now instead of aspirin, the people are taking a 
cholesterol-lowering medication like Crestor, Lipitor, or 
Zocor to prevent having a heart attack. Using the choices 
on the graph, how many people would you say will have a 
heart attack in the next 10 years? (Do you think that taking 
the cholesterol medication will change the number of people 
who will have a heart attack? Will the number go up or down? 
How much will it go up or down? Remember, you can choose 
any answer). You are saying that (x) people taking 
cholesterol medication will have a heart attack in the next 
10 years? 
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Now we are going to talk about strokes. 
 
14 Let’s again think about 100 people who are just like you. 
These people have the same health problems you do, but 
they are not taking any medicines to prevent stroke. Over 
the next 10 years, a certain number of these people will 
have a stroke. Using the choices on the graph, how many 
of these people do you think will have a stroke in the next 
10 years? (Choose the bar that is closest to what you think 
the answer is). So you are saying that (x) people with your 
same health problems will have a stroke in the next 10 
years? 
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15 Now these 100 people who are just like you are taking a 
daily aspirin to prevent stroke. Using the choices on the 
graph, how many of these 100 people do you think will 
have a stroke in the next 10 years? (Choose the bar that is 
closest to what you think the answer is) (Do you think that 
taking aspirin will change the number of people who will have 
a heart stroke? Will the number go up or down? How much 
will it go up or down? Remember, you can choose any 
answer).  You are saying (x) people taking aspirin will 
have a stroke in the next 10 years? 
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16 Now instead of taking aspirin to prevent stroke, these 100 
people who are just like you are taking a blood pressure 
pill (Diovan, Dyazide, Toprol, Lopressor) to prevent 
stroke. Using the choices on the graph, how many of 
these 100 people do you think will have a stroke in the 
next 10 years? (Choose the bar that is closest to what you 
think the answer is).  You are saying (x) people taking 
blood pressure medication will have a stroke in the next 
10 years?  
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MEDICATION ADHERENCE (MA) 
 
17 Would you say that your health is excellent, very good, good, fair, or poor?  
 Ex – 1 
Vg – 2 
 G – 3 
 F – 4            
 P – 5 
 Ref - 7  
 Dk – 8 
 
 
18 Would you say that the number of medications you take on a daily basis is 
about right, too many, or too few?          
 AR-1 
 TM-2 
 TF -3 
 REF - 7           
 DK - 8 
 
 
19 How many doses of medication would you say you have missed in the past 2 days?  
 _______ 
 
 
20 Do you ever forget to take your medicines?   
1 Yes 
2 No 
Are you sometimes careless about taking your medicines? 
1 Yes 
2 No 
When you feel better, do you sometimes stop taking your everyday medicines? 
1 Yes 
2 No 
Sometimes, if taking your everyday medicines makes you feel worse, do you not take 
them?   
1 Yes 
2 No 
 
 
Now I am going to ask you a few questions about medication(s) you take.  
 
 
21 Do you take a daily aspirin?       
 yes - 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
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22 About how long have you been taking aspirin? Would you say. . .    
 <1 yr – 1 
 1-5 yr – 2 
 6-10 yr – 3 
 >10 yr – 4 
 ref – 7 
 dk – 8 
 na – 9 
 
 
23 Did you ever have a bad side effect from taking aspirin?    
 yes - 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
 
 
24 What was it?______________        
 GI bleed – 1 
 upset GI – 2 
 tinnitus – 3 
 Other – 4          
 false – 5   
 ref – 7 
 dk – 8 
 na – 9 
 
 
25 Did you stop taking the aspirin after that?     
 yes – 1 
 no – 2 
 dose red – 3  
 ref – 7 
 dk – 8 
 na – 9 
 
 
26 Did you discuss the bad side effect with your doctor?     
 yes – 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
 
 
27 Do you take a cholesterol medication?       
 yes – 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
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28 About how long have you been taking a statin? Would you say. . .    
 <1 yr – 1 
 1-5 yr – 2 
 6-10 yr – 3 
 >10 yr – 4 
 ref – 7 
 dk – 8 
 na – 9 
 
 
29 Did you ever have a bad side effect from taking the statin?    
 yes – 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
 
 
30 What was it?______________      
 lgcramp – 1 
 Lft bump – 2 
 Other – 4          
 false – 5   
 ref – 7 
 dk – 8 
 na – 9 
 
 
31 Did you stop taking the statin after that?       
 yes - 1 
 no – 2 
 dose red – 3  
 ref – 7 
 dk – 8 
 na – 9 
 
 
32 Did you discuss the bad side effect with your doctor?     
 yes - 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
 
 
33 Do you take blood pressure medication?       
 yes - 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
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34 About how long have you been taking bp meds? Would you say. . .  
 <1 yr – 1 
 1-5 yr – 2 
 6-10 yr – 3 
 >10 yr – 4 
 ref – 7 
 dk – 8 
 na – 9 
 
 
35 Did you ever have a bad side effect from taking bp meds?   
 yes - 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
 
 
36 What was it?______________      
 weakness – 1 
 fall – 2 
 cough – 3 
 Other – 4          
 false – 5   
 ref – 7 
 dk – 8 
 na – 9 
 
 
37 Did you stop taking the bp med after that?      
 yes - 1 
 no – 2 
 dose red – 3  
 ref – 7 
 dk – 8 
 na – 9 
 
 
38 Did you discuss the bad side effect with your doctor?   
 yes - 1 
 no – 2 
 ref – 7 
 dk – 8 
 na – 9 
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GENERAL DESCRIPTIVE INFO (GDI) 
 
39 Do you live alone?        
 yes – 1 
 No – 2  
 Ref – 7  
 Dk – 8  
 
 
40 Who lives with you? yes  no  ref  dk na 
 
 a. spouse  1  2  7  8 9 
 b. child   1  2  7  8 9 
 c. other relative 1  2  7  8 9 
 d. friend  1  2  7  8 9 
 e. paid employee 1  2  7  8 9 
 f. other__________ 1  2  7  8 9 
 
 
41 Which of the following best describes your current marital status   
 single - 1 
 married – 2 
 divorced – 3           
 widowed – 4           
 ref - 7   
 dk - 8 
 
42 How many years of school did you finish?     ______ 
 
 
 
43 Do you need assistance with_______?  
 
No assistance Needs assistance 
Telephone use 
 
No – 0   Yes – 1   
Shopping for groceries 
 
No – 0  Yes – 1   
Transportation 
 
No – 0  Yes – 1  
Meal preparation 
 
No – 0  Yes – 1  
Housework 
 
No – 0  Yes – 1  
Taking medications 
 
No – 0  Yes – 1  
Handling finances 
 
No – 0  Yes – 1  
TOTAL   
 
 
44   DOES INTERVIEWER THINK PARTICIPANT UNDERSTOOD GIST OF SURVEY? 
 No - 0 
 Yes - 1 
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